Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill
The Section 232 investigation gives generic manufacturers an opportunity to highlight supply chain vulnerabilities. (Shutterstock)

More from Generics

More from Biosimilars & Generics